Women with BRCA1 and BRCA2 mutations survive ovarian cancer at higher rates than those without mutations

January 24, 2012, by DCEG Staff

Results from a National Cancer Institute (NCI) sponsored multi-center study published in the Journal of the American Medical Association on January 25, 2012, provides strong evidence that BRCA1 and BRCA2 gene mutation carriers with ovarian cancer were more likely to survive in the five years following diagnosis than were women with ovarian cancer who do not have mutations in these genes.